Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 clinical trial of ARX-1796

Trial Profile

A phase 1 clinical trial of ARX-1796

Planning
Phase of Trial: Phase I

Latest Information Update: 08 May 2018

At a glance

  • Drugs ARX-1796 (Primary)
  • Indications Gram-negative infections
  • Focus Adverse reactions
  • Most Recent Events

    • 08 May 2018 New trial record
    • 01 May 2018 According to an Arixa Pharmaceuticals media release, the company anticipates initiating Phase 1 clinical testing by mid-2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top